Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GUSB | P08236 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 6/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5866291 | 1.00 | NOD2 (0.47) | NOD2SLC16A3MCL1HPGDTSHR | |
| SCHEMBL5866211 | 0.90 | GUSB (0.55) | NOD2SLC16A3MCL1GUSBCCR2 | |
| SCHEMBL5866205 | 0.90 | GUSB (0.55) | NOD2SLC16A3MCL1GUSBCCR2 | |
| SCHEMBL5866368 | 0.88 | GAA (0.46) | NOD2GUSBARCCR2CA12 | |
| SCHEMBL5866378 | 0.88 | GAA (0.46) | NOD2GUSBARCCR2CA12 | |
| SCHEMBL5866227 | 0.85 | CCR2 (0.42) | TSHRGUSBCCR2CA12CA1 | |
| SCHEMBL5866219 | 0.85 | CCR2 (0.42) | TSHRGUSBCCR2CA12CA1 | |
| SCHEMBL5866288 | 0.83 | SLC16A3 (0.49) | NOD2SLC16A3MCL1HPGDTSHR | |
| SCHEMBL5866209 | 0.81 | ALDH1A1 (0.48) | MCL1CCR2CA12CA1CA2 | |
| SCHEMBL5866204 | 0.81 | ALDH1A1 (0.48) | MCL1CCR2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074820-B2 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | claimed |
| EP-0917528-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-18 | — | — | EP | claimed |
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | ANTONSSON THOMAS (SE) | 2002-04-04 | — | — | US | claimed |
| US-6221898-B1 | ANTICOAGULANTS | ASTRA AKTIEBOLAG (SE) | 2001-04-24 | — | — | US | claimed |
| JP-2000515505-A | — | — | 2000-11-21 | — | — | JP | claimed |
| EP-0917528-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-05-26 | — | — | EP | claimed |
| WO-1998001422-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-01-15 | — | — | WO | claimed |
| EP-0917528-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | SERPINC1, F2, SERPINE1 | NOD2 2736/4885SLC16A3 4754/4885MCL1 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.